MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates.
Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability.
Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.
Company Details
- Employees
- 72
- Address
- Ole Maaløes Vej 3, Copenhagen,capital Region 2200,denmark
- pb****@****vax.com
- Industry
- Biotechnology
- Website
- minervax.com
- Keywords
- Group B Streptococcal and GBS.
- HQ
- Copenhagen, Capital Region
Minervax Aps Questions
Minervax Aps's website is minervax.com
Minervax Aps's LinkedIn profile is https://dk.linkedin.com/company/minervax-aps
Minervax Aps has
72 employees.
View email and phone details for 72
employees at Minervax Aps.
Minervax Aps's industry is
Biotechnology
Minervax Aps's top competitors are
Nmd Pharma A/s,
Acesion Pharma,
Immudex,
Io Biotech,
Hemab Therapeutics,
Hoba Therapeutics,
Zealand Pharma,
Muna Therapeutics,
Adcendo,
Genmab.
Minervax Aps's support email address is pbf@minervax.com
Minervax Aps's categories are Biotechnology
